Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

Journal of Medical Economics

Volumn 16, Issue 1, 2013, Pages 150-159

  Sanon, Myrlene ^a   Taylor, Douglas C A ^a   Parthan, Anju ^a   Coombs, John ^b   Paolantonio, Marc ^b   Sasane, Medha ^b  

^a OPTUM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cost effectiveness; GIST; Imatinib

Indexed keywords

IMATINIB;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; QUALITY OF LIFE; TREATMENT DURATION; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; PIPERAZINES; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; UNITED STATES;

EID: 84870932590     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.709204     Document Type: Article

References (29)

1. D'Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44-56
2. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992-2000. Am J Gastroenterol 2005;100:162-68 (Pubitemid 41623284)
3. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-29 (Pubitemid 40216412)
4. Bümming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006;93:836-43
5. Rubin J, Sanon M, Taylor D, et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med 2011;14:121-30
6. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8 (Pubitemid 30043939)
7. Gold JS, Gönen M, Gutié rrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 2009;10:1045-52
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78 (Pubitemid 44520713)
9. Blanke CD, Demetric GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5 (Pubitemid 351264357)
10. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65 (Pubitemid 34747864)
11. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009;28:097-104
12. Joensuu, et al. Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 29, No 15-suppl (May 20 Supplement), 2011: LBA1
13. Sonnenberg FA, Beck Jr. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-38 (Pubitemid 24013155)
14. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(2 Suppl):S1-S29
15. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-34 (Pubitemid 39296599)
16. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38 (Pubitemid 44528723)
17. Contreras-Herná ndez I, Mould-Quevedo JF, Silva A, et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer 2008;98:1762-8 (Pubitemid 351748835)
18. National Vitals Statistics Report. United States Life Tables Report 2004. http:// www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-09.pdf. Accessed September 1, 2008
19. Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig 2007;27:85-93 (Pubitemid 46143283)
20. Heintz D, Noronha-Jackson A, Green S, et al. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk for recurrence: A randomized Phase III study. Trial Study report- data on file Novartis
21. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: Systematic review and economic evaluation. Health Technol Assess 2005;9:1-142
22. Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 2008;44:972-7
23. Hanmer J, Lawrence W, Anderson J, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality of life scores. Med Decis Making 2006;26:391-400 (Pubitemid 44050843)
24. Drug topics red book. Montvale, NJ: Thomson Healthcare, 2010 Physician's Fee and Coding Guide, Volume 1. Duluth, GA: MAG Mutual Healthcare Solutions, Inc, 2010 DRG Expert. 24th ed. Ingenix, 2010
25. Measuring price change for medical care in the CPI. http://www.bls.gov/ cpi/ cpifact4.htm. Accessed July 13, 2011
26. Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(2 Suppl):ii35-8
27. Novartis Pharmaceuticals UK Ltd. Glivec in the treatment of unresectable and/ or metastatic KITpositive gastrointestinal stromal tumours (GISTs) in the United Kingdom: A submission to the National Institute for Clinical Excellence. 2003
28. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100:630-41
29. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5 (Pubitemid 43261756)